Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
Rockingham General Hospital, Perth, Western Australia, Australia.|School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia.
Samantha
S
Bowyer
Department of Medical Oncology, Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Victoria, Australia.|Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Prashanth
P
Prithviraj
The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
Paul
P
Lorigan
Royal Marsden Hospital NHS Foundation Trust, London, UK.
James
J
Larkin
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Grant
G
McArthur
Princess Alexandra Hospital, Greenslopes Private Hospital, Brisbane, Queensland, Australia.
Victoria
V
Atkinson
School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia.|Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Michael
M
Millward
Westmead Hospital, Sydney, New South Wales, Australia.
Muoi
M
Khou
Royal Marsden Hospital NHS Foundation Trust, London, UK.
Stefan
S
Diem
Melanoma Institute Australia, Sydney, New South Wales, Australia.
Sangeetha
S
Ramanujam
Westmead Hospital, Sydney, New South Wales, Australia.
Ben
B
Kong
Melanoma Institute Australia, Sydney, New South Wales, Australia.
Elizabeth
E
Liniker
Melanoma Institute Australia, Sydney, New South Wales, Australia.
Alexander
A
Guminski
Box Hill Hospital, Melbourne, Victoria, Australia.
Phillip
P
Parente
Department of Medical Oncology, Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Victoria, Australia.|Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Miles C
MC
Andrews
Department of Medical Oncology, Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Victoria, Australia.
Sagun
S
Parakh
Department of Medical Oncology, Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Victoria, Australia.|Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Jonathan
J
Cebon
Melanoma Institute Australia, Sydney, New South Wales, Australia.|University of Sydney, Sydney, New South Wales, Australia.
Georgina V
GV
Long
Westmead Hospital, Sydney, New South Wales, Australia.|Melanoma Institute Australia, Sydney, New South Wales, Australia.|University of Sydney, Sydney, New South Wales, Australia.
Matteo S
MS
Carlino
Department of Medical Oncology, Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Victoria, Australia.|Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
Oliver
O
Klein
D060908:CTLA-4 Antigen; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma; D061026:Programmed Cell Death 1 Receptor; D012878:Skin Neoplasms
D060908:CTLA-4 Antigen; D000074324:Ipilimumab; D061026:Programmed Cell Death 1 Receptor